Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD

NCT ID: NCT02680197

Last Updated: 2020-07-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 262 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-29
• Study Completion Date: 2017-02-06

Brief Summary

The study was designed to investigate the efficacy and safety of different doses CHF5259 a long acting muscarinic antagonist in patients with moderate to severe COPD.

Detailed Description

Outpatients attending the hospital clinics/study centres will be recruited. Patients with moderate to severe COPD airflow obstruction according to GOLD 2015 criteria.

A total of approximately 300 patients will be enrolled.

Patients are followed during 3 different treatment periods of 4 weeks separated each by 3 weeks wash-out period. The study lasts approximately 21 weeks for each patient and a total of 11 clinic visits is performed during the study.

The primary endpoint is the Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-12h normalised by time on Day 28.

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CHF5259 12.5 μg total daily dose

CHF5259 or Placebo administration:

Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day

Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Day 14: pre-dose spirometry

Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Group Type: EXPERIMENTAL

CHF5259 or Placebo administration

Intervention Type: DRUG

Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

CHF5259 25 μg total daily dose

CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day

Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Day 14: pre-dose spirometry

Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Group Type: EXPERIMENTAL

CHF5259 or Placebo administration

Intervention Type: DRUG

Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

CHF5259 50 μg total daily dose

CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day

Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Day 14: pre-dose spirometry

Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Group Type: EXPERIMENTAL

CHF5259 or Placebo administration

Intervention Type: DRUG

Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

CHF5259 100μg total daily dose

CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day

Interventions :

Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Day 14: pre-dose spirometry

Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Group Type: EXPERIMENTAL

CHF5259 or Placebo administration

Intervention Type: DRUG

Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

CHF5259 matched Placebo BID

CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day

Interventions :

Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Day 14: pre-dose spirometry

Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram

Group Type: PLACEBO_COMPARATOR

CHF5259 or Placebo administration

Intervention Type: DRUG

Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

Interventions

CHF5259 or Placebo administration

Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged ≥ 40 years

2. Patients with a diagnosis of stable COPD at least 12 months before screening visit.

3. Current smoker or ex-smoker with a smoking history of at least 10 pack-years

4. - A post-bronchodilator FEV1 ≥ 40% and ≤70% of the predicted normal value and,

• a post-bronchodilator FEV1/FVC < 0.7 and,
• a change in FEV1 from the pre-bronchodilator value (reversibility) of at least 5% at screening

5. Patients under bronchodilators with long-acting muscarinic antagonist or long-acting 2 agonist (monotherapy or dual therapy), or patients under ICS + LABA (long-acting beta2-agonist) or ICS (Inhaled Corticosteroids) + LAMA (Long Acting Muscarinic Agonist) for at least 4 weeks prior to screening.

(Patients with a FEV1<50% of the predicted value and a history of 1 exacerbation within the last 12 months must have been treated with ICS+LABA or ICS+LAMA before screening)

6. Ability and cooperative attitude to understand and to perform required outcome measurements of the protocol (e.g. spirometry manoeuvres) and ability to understand the risks involved. Ability to be trained to use the dry powder inhalers.

Exclusion Criteria

1. Diagnosis of asthma or other respiratory disorders (other than COPD) which may interfere with data interpretation according to the investigator's opinion.

2. Patients had a COPD exacerbation or a lower respiratory tract infection within 8 weeks prior to screening, or during the run-in period, that resulted in the use of an antibiotic, or oral or parenteral corticosteroids, or hospitalisation.

3. Patients with a history of ≥ 2 exacerbations within the last 12 months prior to screening.

4. Patients treated with oral/parenteral β2-agonists or nebulised bronchodilators or phosphodiesterase inhibitors or who received LABA/LAMA/ICS treatment therapy in the 4 weeks prior to screening and during the run-in period.

5. Patient is on an inhaled corticosteroid that has been initiated, or the effective dose has been changed, within 4 weeks prior to screening or during the run-in period (patients on stable dose of ICS for at least 4 weeks prior to screening are allowed).

6. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.

7. Patients with known respiratory disorders other than COPD including but not limited to alpha1 antitrypsin deficiency, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease.

8. Patients with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic.

9. Patients who have unstable concurrent disease that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study;

10. Patients who have a concomitant disease of poor prognosis (e.g., cancer...).

11. Patients who have clinically significant cardiovascular condition diagnosed in the last 6 months

12. Patients with known atrial fibrillation (AF):

1. Paroxysmal Atrial Fibrillation

2. Persistent

3. Long standing persistent.

4. Permanent

13. Patients with a clinically significant abnormal 12-lead ECG that might, in the judgment of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study.

14. Patients whose electrocardiogram 12-lead ECG shows a QTcF>450 ms for males or QTcF > 470 ms for females.

15. Patients with clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study.

16. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to use a highly effective birth control methods

17. Patients known to have intolerance/hypersensitivity or any contra-indication to treatment with M3 Antagonist or any of the excipients contained in the formulations used in the study.

18. Patients who have evidence of alcohol or drug abuse, not compliant with the study protocol or not compliant with the study treatments according to investigator's judgment.

19. Patients with major surgery in the previous 3 months or planned during the trial which may affect patient's compliance in study procedures.

20. Patients who have participated in another clinical trial with an investigational drug in the 2 months preceding the screening.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chiesi Farmaceutici S.p.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kai-Michael BEEH, MD

Role: PRINCIPAL_INVESTIGATOR

Institut fuer Atemwegsforschung GmbH

Locations

Clinical Trial Site 203-002

Karlovy Vary, , Czechia

Clinical Trial Site 203-003

Kralupy nad Vltavou, , Czechia

Clinical Trial Site 203-001

Mělník, , Czechia

Clinical Trial Site 203-007

Mladá Boleslav, , Czechia

Clinical Trial Site 203-005

Moravský Krumlov, , Czechia

Clinical Trial Site 203-006

Teplice, , Czechia

Clinical Trial Site 203-004

Varnsdorf, , Czechia

Clinical Trial Site 276-003

Bonn, , Germany

Clinical Trial Site 276-004

Cottbus, , Germany

Clinical Trial Site 276-006

Freiburg im Breisgau, , Germany

Clinical Trial Site 276-002

Großhansdorf, , Germany

Clinical Trial Site 276-005

Stuttgart, , Germany

Clinical Trial Site 276-001

Wiesbaden, , Germany

Clinical Trail Site 348-006

Budapest, , Hungary

Clinical Trial Site 348-003

Budapest, , Hungary

Clinical Trial Site 348-004

Budapest, , Hungary

Clinical Trial Site 348-001

Deszk, , Hungary

Clinical Trial Site 348-005

Komárom, , Hungary

Clinical Trial Site 348-002

Létavértes, , Hungary

Clinical Trail Site 348-008

Miskolc, , Hungary

Clinical Trail Site 348-009

Seregélyes, , Hungary

Clinical Trail Site 348-007

Szombathely, , Hungary

Clinical Trial Site 642-005

Bacau, , Romania

Clinical Trial Site 642-003

Brasov, , Romania

Clinical Trial Site 642-007

Bucharest, , Romania

Clinical Trial Site 642-008

Bucharest, , Romania

Clinical Trial Site 642-004

Cluj-Napoca, , Romania

Clinical Trial Site 642-001

Codlea, , Romania

Clinical Trial Site 642-002

Miercurea-Ciuc, , Romania

Clinical Trial Site 642-006

Suceava, , Romania

Countries

Czechia; Germany; Hungary; Romania

References

Beeh KM, Emirova A, Prunier H, Santoro D, Nandeuil MA. Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT). Int J Chron Obstruct Pulmon Dis. 2018 May 25;13:1701-1711. doi: 10.2147/COPD.S168493. eCollection 2018.

Reference Type: RESULT

PMID: 29872288 (View on PubMed)

Related Links

http://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000558-40/results

Study Record on EU Clinical Trials Register including results

Other Identifiers

2015-000558-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CCD-06302AA1-01

Identifier Type: -

Identifier Source: org_study_id